Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
2023-01-26 09:14
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030
2022-12-06 20:00
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
2022-11-15 20:00
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030
2022-11-02 09:00
CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA
2022-08-04 21:00
Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever
2022-07-28 21:00
Daewoong Pharmaceutical Gets First Korean US FDA Fast-Track for New Idiopathic Pulmonary Fibrosis Drug
2022-07-20 21:00
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
2022-06-24 21:00
Daewoong Pharmaceutical announced first-quarter 2022 results
2022-05-05 21:00
HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative
2022-04-13 08:00
/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/
2022-04-12 15:34
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue Tablets to the Philippines
2022-03-29 09:00
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
2022-02-25 22:00
Daewoong Pharmaceutical Posts Record Annual Revenue in 2021, with Export Growth of Nabota and New Drug Development
2022-02-21 22:00
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug
2022-01-25 22:00
Maypharm Launches a New Professional set HAIRNA for Hair Loss Solution
2021-12-24 17:47
Maypharm Launches New PLA meNnus for Collagen Regeneration
2021-11-05 17:30
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters
2021-11-02 21:00
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials
2021-09-27 21:00
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
2021-08-19 21:00
1
2
3